DEXCOM INC (DXCM): Results of Operations and Financial Condition
DEXCOM INC (DXCM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Dexcom Reports Second Quarter 2026 Financial Results SAN DIEGO - (BUSINESS WIRE-July 30, 2026) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights: • Revenue grew 1
How this was made
The 30-second read
Why it matters
The filing provides a full earnings datapoint set (revenue, GAAP and non-GAAP operating income, net income) and, crucially, raised FY2026 guidance for revenue and multiple margin/EBITDA measures. It also adds new clinical trial results (CONNECT) and a product/app launch update (reimagined Stelo app).
Market read
Traders can update DXCM valuation models immediately using the raised FY2026 revenue and margin guidance, and incorporate the new trial and consumer-app catalysts into adoption expectations.
What to watch
The release emphasizes non-GAAP metrics and provides limited detail on unit growth, pricing, and reimbursement headwinds; traders may discount guidance if underlying drivers are unclear.
Dexcom Reports Second Quarter 2026 Financial Results
Revenue grew 13% year-over-year to $1.308 billion, while GAAP operating margin increased 590 basis points to 24.3% and Dexcom raised the midpoint of fiscal year 2026 revenue guidance while increasing non-GAAP margin guidance.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| RevenueGAAP | $1,308.4 million | – | 13% |
| Organic revenueother | $1.298 billion | – | 12% |
| Cost of salesGAAP | $478.4 million | – | – |
| Gross profitGAAP | $830.0 million | – | – |
| Gross profit marginGAAP | 63.4% of revenue | – | – |
| Gross profitnon-GAAP | $838.5 million | – | – |
| Gross profit marginnon-GAAP | 64.1% of reported revenue | – | – |
| Research and developmentGAAP | $153.0 million | – | – |
| Selling, general and administrativeGAAP | $358.7 million | – | – |
| Total operating expensesGAAP | $511.7 million | – | – |
| Operating incomeGAAP | $318.3 million | – | an increase of 590 basis points |
| Operating income marginGAAP | 24.3% of revenue | – | an increase of 590 basis points |
| Operating incomenon-GAAP | $328.3 million | – | an increase of 590 basis points |
| Operating income marginnon-GAAP | 25.1% of reported revenue | – | an increase of 590 basis points |
| Other income (expense), netGAAP | $(0.8) million | – | – |
| Income before income taxesGAAP | $317.5 million | – | – |
| Income tax expenseGAAP | $68.4 million | – | – |
| Net incomeGAAP | $249.1 million | – | – |
| Net incomenon-GAAP | $269.1 million | – | – |
| Basic net income per shareGAAP | $0.65 | – | – |
| Diluted net income per shareGAAP | $0.64 | – | – |
| Diluted net income per sharenon-GAAP | $0.70 | – | – |
| Shares used to compute diluted net income per shareGAAP | 390.1 million | – | – |
| Six months ended June 30 revenueGAAP | $2,500.3 million | – | – |
| Six months ended June 30 gross profitGAAP | $1,580.3 million | – | – |
| Six months ended June 30 operating incomeGAAP | $573.6 million | – | – |
| Six months ended June 30 net incomeGAAP | $448.6 million | – | – |
| Six months ended June 30 diluted net income per shareGAAP | $1.15 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| United StatesReported basis. | $933.4 million | – | 11% |
| InternationalReported basis. | $375.0 million | – | 19% |
| DistributorRevenue by customer sales channel. | $1,102.4 million | – | – |
| DirectRevenue by customer sales channel. | $206.0 million | – | – |
fiscal year 2026 outlook
- Revenue$5.18 - $5.25 billion (approximately 11-13% growth)
- Gross marginNon-GAAP Gross Profit Margin of approximately 64%
- NoteNon-GAAP Operating Margin of approximately 23.5-24%
- NoteAdjusted EBITDA Margin of approximately 31.5-32%
What drove it
- Worldwide revenue grew 13% year-over-year to $1.308 billion on a reported basis and 12% year-over-year on an organic basis.
- U.S. revenue grew 11% and international revenue grew 19% on a reported basis, all on a year-over-year basis.
- Second quarter 2026 organic revenue was $1.298 billion and excludes $9.9 million of foreign exchange impact and $0.2 million of acquired non-CGM revenue.
- Dexcom initiated launch of the fully reimagined Stelo app experience, including AI-driven insights and enhanced food logging capabilities.
- Dexcom announced positive results from the CONNECT randomized controlled trial among people with type 2 diabetes not using insulin.
Concerns
- Other income (expense), net was $(0.8) million in the second quarter of 2026, compared to $28.5 million in the second quarter of 2025.
- The second quarter 2026 non-GAAP net income excludes $10.0 million of loss from equity investments.
- Inventory was $726.4 million at June 30, 2026, compared to $629.1 million at December 31, 2025.
What to watch
- Delivery against fiscal year 2026 revenue guidance of $5.18 - $5.25 billion.
- Delivery against non-GAAP gross profit margin guidance of approximately 64%.
- Delivery against non-GAAP operating margin guidance of approximately 23.5-24% and adjusted EBITDA margin guidance of approximately 31.5-32%.
- International revenue growth, which was 19% on a reported basis in the second quarter of 2026.
- Dexcom's continued expansion of production capacity and exploration of new market opportunities.
Balance sheet and cash flow
- As of June 30, 2026, Dexcom held $1.95 billion in cash, cash equivalents and marketable securities.
- Cash and cash equivalents were $1,105.0 million at June 30, 2026, compared to $917.7 million at December 31, 2025.
- Short-term marketable securities were $842.0 million at June 30, 2026, compared to $1,081.0 million at December 31, 2025.
- Long-term senior convertible notes were $1,242.8 million at June 30, 2026, compared to $1,240.9 million at December 31, 2025.
- The revolving credit facility remains undrawn.
- Property and equipment, net was $1,577.2 million at June 30, 2026, compared to $1,559.9 million at December 31, 2025.
- Inventory was $726.4 million at June 30, 2026, compared to $629.1 million at December 31, 2025.
Analysis
Dexcom reported second-quarter revenue of $1.308 billion, up 13% year-over-year on a reported basis, with organic revenue of $1.298 billion, up 12%. U.S. revenue grew 11% on a reported basis and international revenue grew 19% on a reported basis. Revenue by sales channel was $1,102.4 million through distributors and $206.0 million through direct customers. The company also reported six-month revenue of $2,500.3 million, compared with $2,193.1 million in the prior-year period.
Profitability improved materially. GAAP gross profit was $830.0 million, or 63.4% of revenue, compared with $688.8 million, or 59.5% of revenue, a year earlier. Non-GAAP gross profit was $838.5 million, or 64.1% of reported revenue, compared with $695.9 million, or 60.1% of reported revenue. GAAP operating income was $318.3 million, or 24.3% of revenue, and non-GAAP operating income was $328.3 million, or 25.1% of reported revenue. Both operating-margin measures increased 590 basis points from the second quarter of 2025.
GAAP net income was $249.1 million, or $0.64 per diluted share, versus $179.8 million, or $0.45 per diluted share, in the second quarter of 2025. Non-GAAP net income was $269.1 million, or $0.70 per diluted share, versus $192.8 million, or $0.48 per diluted share. The second-quarter non-GAAP net-income exclusions included $9.4 million of amortization of intangible assets, $0.6 million of business transition and other significant items, and $10.0 million of loss from equity investments.
Liquidity included $1.95 billion in cash, cash equivalents and marketable securities as of June 30, 2026, and the revolving credit facility remained undrawn. Long-term senior convertible notes were $1,242.8 million. Inventory was $726.4 million, compared with $629.1 million at December 31, 2025, while property and equipment, net was $1,577.2 million, compared with $1,559.9 million at December 31, 2025. Management stated that the cash balance provides flexibility as Dexcom expands production capacity and explores new market opportunities.
Dexcom raised the midpoint of fiscal year 2026 revenue guidance to $5.18 - $5.25 billion, representing approximately 11-13% growth, and increased guidance for non-GAAP gross profit margin, non-GAAP operating margin and adjusted EBITDA margin. The guide calls for approximately 64% non-GAAP gross profit margin, approximately 23.5-24% non-GAAP operating margin, and approximately 31.5-32% adjusted EBITDA margin. The filing does not provide the prior numerical outlook, so the size of the guidance changes cannot be quantified from the document.
Management, verbatim
This quarter’s performance and the successful outcomes from our CONNECT trial reinforce our confidence in the path ahead and position us well to deliver on our long-range plan.
Jake Leach, Dexcom’s president and CEO
Not in the filing
stated, not guessed- Previous-release outlook and prior numerical guidance figures
- Operating cash flow
- Free cash flow
- Capital expenditures
- Share repurchases during the reported quarter
- Dividend declaration or payment
- GAAP gross-margin guidance
- Fiscal year 2026 operating-expense guidance
- Fiscal year 2026 tax-rate guidance
- CFO commentary
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC 8-K (Item 2.02) with Dexcom’s Q2 2026 financial results and an attached earnings release (Exhibit 99.1).
Ticker impact
Dexcom reported Q2 2026 results and raised FY2026 revenue and margin guidance, including CONNECT trial positive outcomes and Stelo app relaunch.
Likely positive bias for DXCM shares into the next trading sessions as traders reprice FY2026 revenue and margin expectations.
The filing discloses multiple fresh, decision-relevant items: Q2 financials, specific raised FY2026 guidance ranges, and new clinical trial and product/app updates that can affect demand and adoption assumptions.
Market effects
CGM peers may see read-across on demand durability and margin trajectory if investors treat Dexcom’s guidance raise as sector signal.
International revenue growth outpacing U.S. growth may shift attention to non-U.S. reimbursement and distribution dynamics for medtech/diabetes tech.
Clinical trial positive results and consumer app enhancements can influence global CGM adoption narratives and payer discussions.
Counterpoint
Raised guidance could already be partially anticipated; the market may focus on whether margins are sustainable given production capacity expansion and competitive pricing.
Key entities
- companyDexcom, Inc.
Nasdaq-listed CGM company reporting Q2 2026 results and raising FY2026 guidance; also highlights CONNECT trial and Stelo app launch.
- clinical_trialCONNECT randomized controlled trial
Trial results cited as showing clinically meaningful and statistically significant glucose control improvements for type 2 diabetes patients not using insulin.
- productStelo app
Fully reimagined Stelo app experience launch with AI-driven insights and enhanced food logging capabilities.
%252FDexcom%252520headquarters%252520building%252520By%252520MichaelVi.jpeg&w=3840&q=75)